{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T21:04:18Z","timestamp":1769115858701,"version":"3.49.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"28","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,5,4]],"date-time":"2020-05-04T00:00:00Z","timestamp":1588550400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.vaccine.2020.04.078","type":"journal-article","created":{"date-parts":[[2020,5,15]],"date-time":"2020-05-15T05:06:59Z","timestamp":1589519219000},"page":"4379-4386","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Policy implications of the potential use of a novel vaccine to prevent infection with Schistosoma mansoni with or without mass drug administration"],"prefix":"10.1016","volume":"38","author":[{"given":"Klodeta","family":"Kura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin S.","family":"Collyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaspreet","family":"Toor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James E.","family":"Truscott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T. Deirdre","family":"Hollingsworth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matt J.","family":"Keeling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roy M.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2020.04.078_b0005","unstructured":"WHO Expert Committee on the Control of Schistosomiasis. Prevention and control of schistosomiasis and soil-transmitted helminthiasis: WHO Technical Report Series N\u00b0 912. 2002. https:\/\/www.who.int\/intestinal_worms\/resources\/who_trs_912\/en\/"},{"key":"10.1016\/j.vaccine.2020.04.078_b0010","unstructured":"WHO | Weekly Epidemiological Record, 13 December 2019, vol. 94, 50 (pp. 601\u2013612). http:\/\/www9.who.int\/wer\/2019\/wer9450\/en\/ (accessed April 27, 2020)."},{"key":"10.1016\/j.vaccine.2020.04.078_b0015","doi-asserted-by":"crossref","first-page":"929","DOI":"10.4049\/jimmunol.169.2.929","article-title":"Cytokine Regulation of Periportal Fibrosis in Humans Infected with Schistosoma mansoni : IFN-\u03b3 Is Associated with Protection Against Fibrosis and TNF-\u03b1 with Aggravation of Disease","volume":"169","author":"Henri","year":"2002","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2020.04.078_b0020","unstructured":"WHO | Schistosomiasis: progress report 2001\u20132011, strategic plan 2012\u20132020. https:\/\/www.who.int\/schistosomiasis\/resources\/9789241503174\/en\/ (accessed April 27, 2020)."},{"key":"10.1016\/j.vaccine.2020.04.078_b0025","doi-asserted-by":"crossref","first-page":"e640","DOI":"10.1016\/S2214-109X(17)30202-4","article-title":"Treatment of preschool children for schistosomiasis","volume":"5","author":"Montresor","year":"2017","journal-title":"Lancet Glob Heal"},{"key":"10.1016\/j.vaccine.2020.04.078_b0030","unstructured":"WHO | Helminth control in school age children: a guide for managers of control programmes. https:\/\/www.who.int\/neglected_diseases\/resources\/9789241548267\/en\/ (accessed April 27, 2020)."},{"key":"10.1016\/j.vaccine.2020.04.078_b0035","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/bs.apar.2014.12.006","article-title":"Modelling the Effects of Mass Drug Administration on the Molecular Epidemiology of Schistosomes","volume":"87","author":"Lamberton","year":"2015","journal-title":"Adv Parasitol"},{"key":"10.1016\/j.vaccine.2020.04.078_b0040","article-title":"Counting down the goals for 9 neglected tropical diseases: What have we learned from quantitative analysis and transmission modeling?","volume":"2018","author":"Hollingsworth","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2020.04.078_b0045","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1186\/s13071-015-1235-1","article-title":"Quantitative analyses and modelling to support achievement of the 2020 goals for nine neglected tropical diseases","volume":"8","author":"Hollingsworth","year":"2015","journal-title":"Parasites Vectors"},{"key":"10.1016\/j.vaccine.2020.04.078_b0050","article-title":"Are we on our way to achieving the 2020 goals for schistosomiasis morbidity control using current world health organization guidelines?","volume":"2018","author":"Toor","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2020.04.078_b0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0065-308X(08)60561-8","article-title":"Helminth Infections of Humans: Mathematical Models, Population Dynamics, and Control","volume":"24","author":"Anderson","year":"1985","journal-title":"Adv Parasitol"},{"key":"10.1016\/j.vaccine.2020.04.078_b0060","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1186\/s13071-015-1157-y","article-title":"What is required in terms of mass drug administration to interrupt the transmission of schistosome parasites in regions of endemic infection?","volume":"8","author":"Anderson","year":"2015","journal-title":"Parasites Vectors"},{"key":"10.1016\/j.vaccine.2020.04.078_b0065","article-title":"The design of schistosomiasis monitoring and evaluation programmes: The importance of collecting adult data to inform treatment strategies for Schistosoma mansoni","author":"Toor","year":"201812","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2020.04.078_b0070","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/bs.apar.2016.06.003","article-title":"Studies of the Transmission Dynamics, Mathematical Model Development and the Control of Schistosome Parasites by Mass Drug Administration in Human Communities","volume":"94","author":"Anderson","year":"2016","journal-title":"Adv Parasitol"},{"key":"10.1016\/j.vaccine.2020.04.078_b0075","unstructured":"WHO | PCT databank. https:\/\/www.who.int\/neglected_diseases\/preventive_chemotherapy\/sch\/en\/ (accessed April 27, 2020)."},{"key":"10.1016\/j.vaccine.2020.04.078_b0080","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1093\/cid\/ciw506","article-title":"Reduced Efficacy of Praziquantel Against Schistosoma mansoni Is Associated with Multiple Rounds of Mass Drug Administration","volume":"63","author":"Crellen","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2020.04.078_b0085","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.actatropica.2012.06.002","article-title":"DNA barcoding of Schistosoma haematobium on Zanzibar reveals substantial genetic diversity and two major phylogenetic groups","volume":"128","author":"Webster","year":"2013","journal-title":"Acta Trop"},{"key":"10.1016\/j.vaccine.2020.04.078_b0090","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/eva.12529","article-title":"Opportunities and challenges for modelling epidemiological and evolutionary dynamics in a multihost, multiparasite system: Zoonotic hybrid schistosomiasis in West Africa","volume":"11","author":"Borlase","year":"2018","journal-title":"Evol Appl"},{"key":"10.1016\/j.vaccine.2020.04.078_b0095","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s13071-018-2656-4","article-title":"Current epidemiological evidence for predisposition to high or low intensity human helminth infection: A systematic review","volume":"11","author":"Wright","year":"2018","journal-title":"Parasites Vectors"},{"issue":"6268","key":"10.1016\/j.vaccine.2020.04.078_b0100","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1126\/science.351.6268.16","article-title":"Unfilled Vials","volume":"351","author":"Cohen","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2020.04.078_b0105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13071-016-1799-4","article-title":"Schistosomiasis vaccines: where do we stand?","volume":"9","author":"Tebeje","year":"2016","journal-title":"Parasites Vectors"},{"key":"10.1016\/j.vaccine.2020.04.078_b0110","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.vaccine.2015.10.027","article-title":"Schistosomiasis vaccine candidate Sm14\/GLA-SE: Phase 1 safety and immunogenicity clinical trial in healthy, male adults","volume":"34","author":"Santini-Oliveira","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.04.078_b0115","article-title":"Safety and efficacy of the rSh28GST urinary schistosomiasis vaccine: A phase 3 randomized, controlled trial in Senegalese children","author":"Riveau","year":"201812","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2020.04.078_b0120","article-title":"Safety and immunogenicity of rSh28GST antigen in humans: Phase 1 randomized clinical study of a vaccine candidate against urinary schistosomiasis","author":"Riveau","year":"20126","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2020.04.078_b0125","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.pt.2016.10.010","article-title":"Sm-p80-Based Schistosomiasis Vaccine: Preparation for Human Clinical Trials","volume":"33","author":"Siddiqui","year":"2017","journal-title":"Trends Parasitol"},{"key":"10.1016\/j.vaccine.2020.04.078_b0130","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.4161\/hv.7.11.17017","article-title":"Schistosomiasis vaccines","volume":"7","author":"Siddiqui","year":"2011","journal-title":"Hum Vaccin"},{"key":"10.1016\/j.vaccine.2020.04.078_b0135","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/nyas.13942","article-title":"Sm-p80-based schistosomiasis vaccine: Double-blind preclinical trial in baboons demonstrates comprehensive prophylactic and parasite transmission-blocking efficacy","volume":"1425","author":"Zhang","year":"2018","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.vaccine.2020.04.078_b0140","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1007\/s00436-014-3879-8","article-title":"Longevity of Sm-p80-specific antibody responses following vaccination with Sm-p80 vaccine in mice and baboons and transplacental transfer of Sm-p80-specific antibodies in a baboon","volume":"113","author":"Zhang","year":"2014","journal-title":"Parasitol Res"},{"key":"10.1016\/j.vaccine.2020.04.078_b0145","article-title":"Soil-Transmitted Helminths: Mathematical Models of Transmission, the Impact of Mass Drug Administration and Transmission Elimination Criteria","author":"Truscott","year":"2016","journal-title":"Adv Parasitol"},{"key":"10.1016\/j.vaccine.2020.04.078_b0150","article-title":"Modelling the impact of a Schistosoma mansoni vaccine and mass drug administration to achieve morbidity control and transmission elimination","author":"Kura","year":"201913","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2020.04.078_b0155","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13071-019-3749-4","article-title":"Vaccination or mass drug administration against schistosomiasis: A hypothetical cost-effectiveness modelling comparison","volume":"12","author":"Collyer","year":"2019","journal-title":"Parasites Vectors"},{"key":"10.1016\/j.vaccine.2020.04.078_b0160","doi-asserted-by":"crossref","unstructured":"Haddison EC, Abdullahi LH, Muloiwa R, Hussey GD, Kagina BM. Comparison of school based and supplemental vaccination strategies in the delivery of vaccines to 5-19 year olds in Africa - a systematic review. F1000Research 2017;6. https:\/\/doi.org\/10.12688\/f1000research.12804.1.","DOI":"10.12688\/f1000research.12804.1"},{"key":"10.1016\/j.vaccine.2020.04.078_b0165","doi-asserted-by":"crossref","unstructured":"Black E, Richmond R. Prevention of cervical cancer in sub-saharan Africa: The advantages and challenges of HPV vaccination. Vaccines 2018;6. https:\/\/doi.org\/10.3390\/vaccines6030061.","DOI":"10.20944\/preprints201807.0217.v1"},{"key":"10.1016\/j.vaccine.2020.04.078_b0170","doi-asserted-by":"crossref","first-page":"e453","DOI":"10.1016\/S2214-109X(16)30099-7","article-title":"Global estimates of human papillomavirus vaccination coverage by region and income level: A pooled analysis","volume":"4","author":"Bruni","year":"2016","journal-title":"Lancet Glob Heal"},{"key":"10.1016\/j.vaccine.2020.04.078_b0175","unstructured":"Immunization coverage. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/immunization-coverage (accessed April 27, 2020)."},{"key":"10.1016\/j.vaccine.2020.04.078_b0180","doi-asserted-by":"crossref","first-page":"A99","DOI":"10.1016\/j.vaccine.2014.12.037","article-title":"Costs of vaccine programs across 94 low- and middle-income countries","volume":"33","author":"Portnoy","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.04.078_b0185","unstructured":"WHO | Making Choices in Health: WHO Guide to Cost-Effectiveness Analysis. https:\/\/www.who.int\/choice\/book\/en\/ (accessed April 27, 2020)."},{"key":"10.1016\/j.vaccine.2020.04.078_b0190","unstructured":"WHO | Use of MenAfriVacTM (meningitis A vaccine) in a controlled temperature chain (CTC) during campaigns. https:\/\/www.who.int\/immunization\/documents\/WHO_IVB_13.04_5_6\/en\/ (accessed April 27, 2020)."},{"key":"10.1016\/j.vaccine.2020.04.078_b0195","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/S1473-3099(17)30301-8","article-title":"Impact of MenAfriVac in nine countries of the African meningitis belt, 2010\u201315: an analysis of surveillance data","volume":"17","author":"Trotter","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2020.04.078_b0200","doi-asserted-by":"crossref","first-page":"25","DOI":"10.2147\/VDT.S53028","article-title":"RTS, S malaria vaccine development: progress and considerations for postapproval introduction","volume":"6","author":"Asante","year":"2016","journal-title":"Vaccine Dev Ther"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20306058?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20306058?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:43:17Z","timestamp":1759401797000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X20306058"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":40,"journal-issue":{"issue":"28","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["S0264410X20306058"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.04.078","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Policy implications of the potential use of a novel vaccine to prevent infection with Schistosoma mansoni with or without mass drug administration","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.04.078","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}